Browsing by Subject "Topoisomerase i"

Now showing items 1-2 of 2

    • Article  

      Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC-ECSG phase II clinical study 

      Gamucci, T.; Paridaens, R.; Heinrich, B.; Schellens, J. H. M.; Pavlidis, Nicholas; Verweij, J.; Sessa, Cristiana; Kaye, Stanley B.; Roelvink, M.; Wanders, J.; Hanauske, A. R. (2000)
      Background: GI147211 is a water-soluble synthetic analogue of camptothecin showing promising in vivo and in vitro antitumor activity and an acceptable toxicity profile. Patients and methods: Between April 1995 and November ...
    • Article  

      Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies 

      Schellens, J. H. M.; Heinrich, B.; Lehnert, M.; Gore, M. E.; Kaye, Stanley B.; Dombernowsky, P.; Paridaens, R.; Oosterom, A. T. Van; Verweij, J.; Loos, W. J.; Calvert, H.; Pavlidis, Nicholas; Cortes-Funes, H.; Wanders, J.; Roelvink, M.; Sessa, Cristiana; Selinger, K.; Wissel, P. S.; Gamucci, T.; Hanauske, A. R. (2002)
      Population pharmacokinetic-dynamic analysis was prospectively integrated in a broad phase II program of lurtotecan (GI147211), a novel camptothecin derived topoisomerase I inhibitor, to determine the population pharmacokinetic ...